Unlocking the power of a patient’s own biology for the treatment of rare diseases

Quince Therapeutics, Inc. is a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases. Our Phase 3 lead asset, eDSP, for the treatment of the rare pediatric neurodegenerative disease Ataxia-Telangiectasia (A-T) is the first product in development that leverages our proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform, which is a novel drug/device combination that uses an automated process designed to encapsulate dexamethasone sodium phosphate into the patient’s own red blood cells.

Enrolling Pivotal Phase 3 NEAT Clinical Trial of eDSP in Patients with A-T

Our strategic focus is to complete the pivotal Phase 3 clinical trial of eDSP, called NEAT (Neurologic Effects of eDSP on Subjects with A-T), to evaluate the safety and efficacy of eDSP for the treatment of Ataxia-Telangiectasia (A-T). A-T is an inherited autosomal recessive neurodegenerative and immunodeficiency disorder with currently no approved therapeutic treatments in any global market for this rare pediatric disease.

Quince is actively enrolling participants for our global Phase 3 NEAT study. Patients with A-T interested in participating can learn more about the NEAT study criteria and locations by visiting Clinicaltrials.gov here and Clinical Trials Information System here.

The U.S. Food and Drug Administration granted Fast Track designation for our eDSP System for the treatment of patients with A-T, underscoring the high unmet medical need as there are currently no approved therapeutic treatments for A-T.

AIDE Technology Platform

Our proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform is an innovative drug/device combination that uses an automated process to encapsulate a drug into a patient’s own red blood cells. Red blood cells have several characteristics that make them a potentially ideal vehicle for drug delivery, including potentially better tolerability, enhanced tissue biodistribution, reduced immunogenicity, and prolongation of circulating half-life. Our AIDE technology is designed to harness many of these benefits to allow for new and improved therapeutic options for patients living with high unmet medical needs.

eDSP is the first product in development that leverages our AIDE technology and is composed of dexamethasone sodium phosphate (DSP) encapsulated in autologous red blood cells targeted for the treatment of patients with A-T. DSP is a corticosteroid well known for its potent anti-inflammatory properties, but is coupled with serious adverse effects, including potential long-term adverse effects due to adrenal suppression. eDSP is designed to maintain the efficacy of corticosteroids while reducing or eliminating the significant adverse effects associated with corticosteroid treatment.

AIDE Technology PlatformPhase 3 NEAT Clinical Trial

Quince in the News